The Keynote kidney cancer clinical trials are studying an investigational drug, pembrolizumab, to see if it is safe and if it helps slow down or stop the growth of kidney cancer. The most common type of kidney cancer is renal cell carcinoma (RCC), which usually grows inside the kidneys.
Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.
Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
You can also call our clinical trial information center at 1-888-577-8839 to learn more.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Safety and Efficacy Study of Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy||564||Renal Cell Carcinoma||Phase 3||Recruiting|
|Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma||426||Renal Cell Carcinoma||Phase 3||Active, not recruiting|
|Study of Pembrolizumab Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma||427||Renal Cell Carcinoma||Phase 2||Active, not recruiting|
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.